Lombard Medical Technologies PLC Admission of shares (3265A)

TIDMLMT

RNS Number : 3265A

Lombard Medical Technologies PLC

19 March 2013

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Admission of shares issued in relation to

the Second Tranche of the May 2011 Fundraising

London, UK, 19 March 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focused on innovative vascular products, is pleased to announce that application has been made for 10,040,000 ordinary shares of 20 pence each, being the total number of ordinary shares being issued under the Second Placing and the Second Subscription, to be admitted to trading on AIM. Admission is expected to become effective on 22 March 2013. Proceeds of this share issue will be c. GBP14.1m before expenses.

The Second Placing and the Second Subscription constitute the second tranche of a two tranche issue of equity by Lombard Medical to raise up to GBP25.3 million (before expenses) and comprising a Placing, Subscription and Offer first announced by Lombard Medical on 20 April 2011. Further details of the Placing, Subscription and Offer were set out in the announcements published by the Company on 20 April 2011 and 25 May 2011.

Definitions used in this announcement will have the same meaning as those used in the circular of Lombard Medical dated 20 April 2011, unless the context requires otherwise.

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix(TM) is currently being commercialised in the EU, and has been approved by the FDA in the US

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com.

For further information:

 
 Lombard Medical Technologies PLC          Tel: 01235 750 800 
 Simon Hubbert, Chief Executive Officer 
  Ian Ardill, Chief Financial Officer 
 Canaccord Genuity Limited                 Tel: 020 7523 8000 
  Lucy Tilley/ Henry Fitzgerald O'Connor 
  / Tim Redfern 
 FTI Consulting                            Tel: 020 7831 3113 
  Simon Conway / Susan Stuart / Victoria 
  Foster Mitchell

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAEDNFFDDEFF

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Oct 2024 to Nov 2024